Genetically adjusted PSA levels for prostate cancer screening

<p>Prostate-specific antigen (PSA) screening for prostate cancer remains controversial because it increases overdiagnosis and overtreatment of clinically insignificant tumors. Accounting for genetic determinants of constitutive, non-cancer PSA variation has potential to improve screening utility. We discovered 128 genome-wide significant associations (<em>P</em>&lt;5&times;10^-8) in a multi-ancestry GWAS meta-analysis of 95,768 men and developed a PSA polygenic score (PGS_PSA) that explains 9.61% of constitutive PSA variation. Here we provide full&nbsp;GWAS&nbsp;summary statistics for the multi-ancestry meta-analysis and ancestry-stratified summary statistics for ~1.2 million variants&nbsp;used to derive a genome-wide PGS_PSA.</p>